[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 24/31, 2001

Linezolid and Reversible Myelosuppression

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(16):1973-1974. doi:10.1001/jama.286.16.1969

To the Editor: Dr Green and colleagues1 reported serious but reversible myelosuppression in patients receiving more than 2 weeks of therapy with linezolid, with bone marrow changes that appear similar to those seen in reversible chloramphenicol toxicity. The structure and mechanism similarities between linezolid and chloramphenicol suggest there may be a shared mechanism for this adverse effect. Linezolid shares with chloramphenicol an antibacterial mechanism involving binding to the ribosomal RNA of the 50s subunit. They also have structural similarities, including the nitro group hypothesized to be the feature of chloramphenicol responsible for aplastic anemia.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×